PIK3CA突变与内分泌抵抗HR+/HER2-转移性乳腺癌一线治疗结局:多中心真实世界研究
本研究基于前瞻性多中心CHAMBER研究,分析内分泌抵抗的HR+/HER2-晚期乳腺癌患者中循环PIK3CA突变的预后价值。337例患者中22%符合内分泌抵抗标准,其中63例可评估PIK3CA状态,突变率为29%。PIK3CA突变是OS和PFS1的负性预后因素,中位OS为65个月(野生型)对36个月(突变型),中位PFS1为22个月对10个月。
要点
- 内分泌抵抗且PIK3CA突变患者预后不良,中位OS仅36个月。
- PIK3CA突变者一线PFS1中位10个月,显著短于野生型的22个月。
- 该人群或需强化治疗策略,支持进一步评估靶向PIK3CA的治疗。
核心结论
- 内分泌抵抗合并PIK3CA突变识别出一组预后不良的HR+/HER2-晚期乳腺癌人群,强化治疗策略具有合理性。
研究设计与样本
- 前瞻性多中心CHAMBER研究的真实世界分析,纳入337例HR+/HER2-晚期乳腺癌患者,其中74例(22%)符合内分泌抵抗标准。
- PIK3CA通过覆盖全外显子区域的NGS panel检测循环肿瘤DNA。
- 内分泌抵抗定义:原发为辅助内分泌治疗前2年内复发;继发为开始内分泌治疗后2年以上或完成内分泌治疗后1年内复发。
主要发现
- 内分泌抵抗人群中性特征:95%女性、5%男性,诊断中位年龄50岁(IQR 44-63),75%女性为绝经后。
- 86%为继发性内分泌抵抗,64%有内脏转移,74%转移部位少于3个,79%接受过一线CDK4/6抑制剂。
- 63/74例可评估PIK3CA状态,突变患病率为29%。
- PIK3CA突变组中位OS为36个月,野生型为65个月(log-rank P=0.024,HR 2.61,95%CI 1.10-6.22)。
- PIK3CA突变组中位PFS1为10个月,野生型为22个月(log-rank P=0.012,HR 2.24,95%CI 1.18-4.26)。
临床怎么用
- 对内分泌抵抗的HR+/HER2-晚期乳腺癌患者,可考虑检测PIK3CA突变以进行预后分层。
- PIK3CA突变合并内分泌抵抗提示高危,应个体化考虑强化一线治疗策略。
局限性
- PIK3CA状态仅在63/74例内分泌抵抗患者中可评估,样本量有限。
- 本研究为真实世界分析,结果需在前瞻性干预研究中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Outcomes and characteristics of endocrine-resistant, PIK3CA-mutated HR+ /HER2- advanced breast cancer patients in real-world are poorly investigated. Here, we explored the role of circulating PIK3CA mutations in endocrine-resistant patients in the ongoing prospective, multicentric CHAMBER study. METHODS: PIK3CA was analyzed by NGS panel covering the full exonic region of PIK3CA gene. Endocrine resistance was defined as: i) primary: relapse during the first 2 years of adjuvant ET, or ii) secondary: relapse after 2 years of starting or within 1 year of completing ET. Overall survival (OS) was calculated from the start of first-line to death from any cause. Progression free survival 1 (PFS1) was calculated from the start of first-line to progression or death. RESULTS: Among the overall CHAMBER population, 22 % patients met the criteria for endocrine-resistance (74/337). The study population consisted in 95 % women and 5 % men; median age at diagnosis was 50 years (IQR 44-63); 75 % of the women was postmenopausal;86 % of the total population presented with a secondary endocrine-resistance, 64 % had visceral relapse, 74 % had less than 3 metastatic sites, 79 % had received first-line CDK4/6 inhibitor. PIK3CA status was available for 63/74 pts, with a 29 % prevalence of mutation. PIK3CAmut was a negative prognostic factor for OS (median 65 [wt] vs 36 months [mut], log-rank p 0.024 HR 2.61 [95 % CI 1.10-6.22]) and PFS1 (median 22 [wt] vs 10 months [mut], log-rank p 0.012, HR 2.24 [95 % CI 1.18-4.26]). CONCLUSION: The co-occurrence of endocrine-resistance and PIK3CAmut identifies a population with unfavorable prognosis, reinforcing the rationale of escalated therapies.
引用
- Dieci MV, Vernaci G, Colangelo C, et al. PIK3CA mutations and first-line outcomes in endocrine-resistant HR+/HER2- metastatic breast cancer: A multicentric real-world study. Eur J Cancer. 2025. PMID: 41435752. doi:10.1016/j.ejca.2025.116194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。